These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
216 related articles for article (PubMed ID: 7498636)
1. Medical costs in community subjects with irritable bowel syndrome. Talley NJ; Gabriel SE; Harmsen WS; Zinsmeister AR; Evans RW Gastroenterology; 1995 Dec; 109(6):1736-41. PubMed ID: 7498636 [TBL] [Abstract][Full Text] [Related]
2. Irritable bowel syndrome, health care use, and costs: a U.S. managed care perspective. Longstreth GF; Wilson A; Knight K; Wong J; Chiou CF; Barghout V; Frech F; Ofman JJ Am J Gastroenterol; 2003 Mar; 98(3):600-7. PubMed ID: 12650794 [TBL] [Abstract][Full Text] [Related]
3. Costs of care for irritable bowel syndrome patients in a health maintenance organization. Levy RL; Von Korff M; Whitehead WE; Stang P; Saunders K; Jhingran P; Barghout V; Feld AD Am J Gastroenterol; 2001 Nov; 96(11):3122-9. PubMed ID: 11721759 [TBL] [Abstract][Full Text] [Related]
4. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population. Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643 [TBL] [Abstract][Full Text] [Related]
5. The economic consequences of irritable bowel syndrome: a US employer perspective. Leong SA; Barghout V; Birnbaum HG; Thibeault CE; Ben-Hamadi R; Frech F; Ofman JJ Arch Intern Med; 2003 Apr; 163(8):929-35. PubMed ID: 12719202 [TBL] [Abstract][Full Text] [Related]
6. The economic impact of irritable bowel syndrome in a managed care setting. Patel RP; Petitta A; Fogel R; Peterson E; Zarowitz BJ J Clin Gastroenterol; 2002 Jul; 35(1):14-20. PubMed ID: 12080220 [TBL] [Abstract][Full Text] [Related]
7. A case-control comparison of direct healthcare-provider medical costs of chronic idiopathic constipation and irritable bowel syndrome with constipation in a community-based cohort. Herrick LM; Spalding WM; Saito YA; Moriarty J; Schleck C J Med Econ; 2017 Mar; 20(3):273-279. PubMed ID: 27783533 [TBL] [Abstract][Full Text] [Related]
8. Irritable bowel syndrome in a community: symptom subgroups, risk factors, and health care utilization. Talley NJ; Zinsmeister AR; Melton LJ Am J Epidemiol; 1995 Jul; 142(1):76-83. PubMed ID: 7785677 [TBL] [Abstract][Full Text] [Related]
9. Risk factors for irritable bowel syndrome: role of analgesics and food sensitivities. Locke GR; Zinsmeister AR; Talley NJ; Fett SL; Melton LJ Am J Gastroenterol; 2000 Jan; 95(1):157-65. PubMed ID: 10638576 [TBL] [Abstract][Full Text] [Related]
10. Epidemiology of colonic symptoms and the irritable bowel syndrome. Talley NJ; Zinsmeister AR; Van Dyke C; Melton LJ Gastroenterology; 1991 Oct; 101(4):927-34. PubMed ID: 1889716 [TBL] [Abstract][Full Text] [Related]
11. Health-related quality of life and health care costs in severe, refractory irritable bowel syndrome. Creed F; Ratcliffe J; Fernandez L; Tomenson B; Palmer S; Rigby C; Guthrie E; Read N; Thompson D Ann Intern Med; 2001 May; 134(9 Pt 2):860-8. PubMed ID: 11346322 [TBL] [Abstract][Full Text] [Related]
12. Celiac disease serology in irritable bowel syndrome and dyspepsia: a population-based case-control study. Locke GR; Murray JA; Zinsmeister AR; Melton LJ; Talley NJ Mayo Clin Proc; 2004 Apr; 79(4):476-82. PubMed ID: 15065612 [TBL] [Abstract][Full Text] [Related]
13. Risk factors for chronic diarrhoea in the community in the absence of irritable bowel syndrome. Chang JY; Locke GR; Schleck CD; Zinsmeister AR; Talley NJ Neurogastroenterol Motil; 2009 Oct; 21(10):1060-e87. PubMed ID: 19460105 [TBL] [Abstract][Full Text] [Related]
14. Prevalence of gastrointestinal symptoms in the elderly: a population-based study. Talley NJ; O'Keefe EA; Zinsmeister AR; Melton LJ Gastroenterology; 1992 Mar; 102(3):895-901. PubMed ID: 1537525 [TBL] [Abstract][Full Text] [Related]
15. The economic burden of irritable bowel syndrome in Canada. Bentkover JD; Field C; Greene EM; Plourde V; Casciano JP Can J Gastroenterol; 1999 Mar; 13 Suppl A():89A-96A. PubMed ID: 10202215 [TBL] [Abstract][Full Text] [Related]
16. Impact of functional gastrointestinal disorders on survival in the community. Chang JY; Locke GR; McNally MA; Halder SL; Schleck CD; Zinsmeister AR; Talley NJ Am J Gastroenterol; 2010 Apr; 105(4):822-32. PubMed ID: 20160713 [TBL] [Abstract][Full Text] [Related]
18. Health-related quality of life, work productivity, and indirect costs among patients with irritable bowel syndrome with diarrhea. Buono JL; Carson RT; Flores NM Health Qual Life Outcomes; 2017 Feb; 15(1):35. PubMed ID: 28196491 [TBL] [Abstract][Full Text] [Related]
19. Health-related quality of life and cost impact of irritable bowel syndrome in a UK primary care setting. Akehurst RL; Brazier JE; Mathers N; O'Keefe C; Kaltenthaler E; Morgan A; Platts M; Walters SJ Pharmacoeconomics; 2002; 20(7):455-62. PubMed ID: 12093301 [TBL] [Abstract][Full Text] [Related]
20. Evidence Against Routine Testing of Patients With Functional Gastrointestinal Disorders for Celiac Disease: A Population-based Study. Choung RS; Rubio-Tapia A; Lahr BD; Kyle RA; Camilleri MJ; Locke GR; Talley NJ; Murray JA Clin Gastroenterol Hepatol; 2015 Nov; 13(11):1937-43. PubMed ID: 25987301 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]